Nygren P - Search Results

1

Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy.

Rendo V, Stoimenov I, Mateus A, Sjöberg E, Svensson R, Gustavsson AL, Johansson L, Ng A, OʼBrien C, Giannakis M, Artursson P, Nygren P, Cheong I, Sjöblom T. Rendo V, et al. Among authors: nygren p. Nat Commun. 2020 Mar 11;11(1):1308. doi: 10.1038/s41467-020-15111-4. Nat Commun. 2020. PMID: 32161261 Free PMC article.

2

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments.

Zhang X, Fryknäs M, Hernlund E, Fayad W, De Milito A, Olofsson MH, Gogvadze V, Dang L, Påhlman S, Schughart LA, Rickardson L, D'Arcy P, Gullbo J, Nygren P, Larsson R, Linder S. Zhang X, et al. Among authors: nygren p. Nat Commun. 2014;5:3295. doi: 10.1038/ncomms4295. Nat Commun. 2014. PMID: 24548894 Free PMC article.

3

A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses.

Kashif M, Andersson C, Åberg M, Nygren P, Sjöblom T, Hammerling U, Larsson R, Gustafsson MG. Kashif M, et al. Among authors: nygren p. Mol Cancer Ther. 2014 Jul;13(7):1964-76. doi: 10.1158/1535-7163.MCT-13-0430. Epub 2014 Apr 22. Mol Cancer Ther. 2014. PMID: 24755197

4

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity.

Karlsson H, Fryknäs M, Strese S, Gullbo J, Westman G, Bremberg U, Sjöblom T, Pandzic T, Larsson R, Nygren P. Karlsson H, et al. Among authors: nygren p. Oncotarget. 2017 May 2;8(18):30217-30234. doi: 10.18632/oncotarget.16324. Oncotarget. 2017. PMID: 28415818 Free PMC article.

5

Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors.

Daskalakis K, Norlén O, Karakatsanis A, Hellman P, Larsson R, Nygren P, Stålberg P. Daskalakis K, et al. Among authors: nygren p. Endocr Relat Cancer. 2018 Apr;25(4):471-480. doi: 10.1530/ERC-17-0404. Epub 2018 Feb 12. Endocr Relat Cancer. 2018. PMID: 29440231

6

Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients.

Csoka K, Nygren P, Graf W, Påhlman L, Glimelius B, Larsson R. Csoka K, et al. Among authors: nygren p. Int J Cancer. 1995 Nov 3;63(3):356-60. doi: 10.1002/ijc.2910630309. Int J Cancer. 1995. PMID: 7591231

7

Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.

Dhar S, Nygren P, Csoka K, Botling J, Nilsson K, Larsson R. Dhar S, et al. Among authors: nygren p. Br J Cancer. 1996 Sep;74(6):888-96. doi: 10.1038/bjc.1996.453. Br J Cancer. 1996. PMID: 8826854 Free PMC article.

8

Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic.

Fridborg H, Jonsson E, Nygren P, Larsson R. Fridborg H, et al. Among authors: nygren p. Eur J Cancer. 1999 Mar;35(3):424-32. doi: 10.1016/s0959-8049(98)00286-x. Eur J Cancer. 1999. PMID: 10448294

9

What is cancer chemotherapy?

Nygren P; SBU-group. Swedish Council on Technology Assessment in Health Care. Nygren P, et al. Acta Oncol. 2001;40(2-3):166-74. doi: 10.1080/02841860151116204. Acta Oncol. 2001. PMID: 11441929 Review.

10

Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.

Berglund A, Glimelius B, Bergh J, Brodin O, Fjällskog ML, Hagberg H, von Heideman A, Larsson R, Tholander B, de la Torre M, Aström G, Oberg K, Parö G, Nygren P. Berglund A, et al. Among authors: nygren p. Med Oncol. 2002;19(3):151-9. doi: 10.1385/MO:19:3:151. Med Oncol. 2002. PMID: 12482125 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

478 results

Search Page

Filters